http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009017274-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259045c6eba6e2c5d338b84e0a88b571 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f65c61be47844d66b6755889e5107628 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de88f1116c71f2e06b901675b74355bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_010cfd10237b8472a5de383b1128e42e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_901588c5fd7e694d395d427b1975b88f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 |
| filingDate | 2007-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f701b1b1e21d104ea90f9d502f4afb58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95e7d1bebe6449e717b5a870e36ea301 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2ebfa11dcecf55b50fc42575506ed0c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8717ec968af5ef19bcae5deb7812dcb8 |
| publicationDate | 2009-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2009017274-A1 |
| titleOfInvention | An agent for differentiating hematopoietic stem cell into natural killer cell comprising yc-1 or il-21 and a method of differentiating hematopoietic stem cell into natural killer cell using thereof |
| abstract | The present invention relates to an agent for differentiating hematopoietic stem cells into natural killer cells and a method for the differentiation, more precisely an agent for differentiating hematopoietic stem cells into natural killer cells comprising YC-I [3- ( 5 ' - hydroxymethyl-2 ' -furyl) -1-benzylindazole] or IL-21 (Interleukin-21) as an active ingredient and a method for differentiating hematopoietic stem cells into natural killer cells using the same. The YC-I and IL-21 regulate the differentiation of hematopoietic stem cells into natural killer cells and increase the killing activity of NK cells. Therefore, the agent for NK cell differentiation of the present invention can be effectively used for cell therapy for the treatment of cancer by regulating the differentiation of hematopoietic stem cells into natural killer cells having tumor cell killing activity. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107760648-A |
| priorityDate | 2007-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 271.